Document is current
Any future updates will be listed below
-
Authors
Davis, Christal N.
Khan, Yousef
Crist, Richard C.
Vickers-Smith, Rachel
Hartwell, Emily E.
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
Kampman, Kyle
Kember, Rachel L. https://orcid.org/0000-0001-8820-2659
Le Moigne, Anne
Laffont, Celine M. https://orcid.org/0000-0001-8345-5980
Kranzler, Henry R. https://orcid.org/0000-0002-1018-0450
-
Funding
Funding for this research was provided by:
U.S. Department of Veterans Affairs (Postdoctoral fellowship, IK2 CX002336, I01 CX001734, I01 BX004820, VISN 4 Mental Illness Research, Education and Clinical Center)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (K01 AA028292)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (P30 DA046345)
Indivior (none)
- License Information
-
More Information
Article History
Received: 4 March 2025
Revised: 21 April 2025
Accepted: 22 April 2025
First Online: 6 May 2025
Competing interests
: ALM and CML are employees of Indivior. HRK is a member of advisory boards for Altimmune and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals and Altimmune; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Imbrium, Indivior, Kinnov, Lilly, Otsuka, and Pear. HRK and ALM are inventors on U.S. provisional patent “Multi-ancestry Genome-wide Association Meta-analysis of Buprenorphine Treatment Response.” The remaining authors have nothing to disclose.
